Parcourir par sujet "muscarinic receptor blocking agent"
Voici les éléments 1-13 de 13
-
The annual direct costs of stable COPD in Greece
(2018)Introduction: Chronic obstructive pulmonary disease (COPD) places a major burden on health care systems and has substantial economic effects; however, the cost of stable disease in Greece has never been thoroughly explored. ... -
Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base
(2018)Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, ... -
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men
(2021)Context: The role of overactive bladder (OAB) treatment in women beyond antimuscarinics has been evaluated extensively. Beta-3 agonists, botulinum toxin-A (BTX-A), and nerve stimulation are indicated in these patients. ... -
Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)
(2017)Aims: To review and assess the definitions of drug resistance and the evidence supporting treatment for drug resistant overactive bladder/detrusor overactivity (OAB/DO). Methods: Evidence review of the extant literature ... -
Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study
(2021)Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial clinical condition, characterized by chronic progressive (or worsening) respiratory symptoms, structural pulmonary abnormalities, and impaired ... -
Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms[Figure presented]
(2017)Context The treatment of nocturia is a key challenge due to the multi-factorial pathophysiology of the symptom and the disparate outcome measures used in research. Objective To assess and compare available therapy options ... -
Missed diagnosis and overtreatment of COPD among smoking primary care population in central Greece: old problems persist
(2018)Background: The diagnosis of COPD is not always consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy in daily clinical practice, especially in primary care. This study aimed to estimate ... -
The muscarinic antagonist gallamine induces proliferation of airway smooth muscle cells regardless of the cell phenotype
(2019)Background: Muscarinic receptor antagonists are a usual treatment for chronic airway diseases, with increased bronchoconstriction, like asthma and chronic obstructive pulmonary disease. These diseases are usually accompanied ... -
Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492–504
(2021)[No abstract available] -
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
(2016)Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ... -
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics
(2022)Background: At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics. Objective: To ... -
Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD
(2018)Long acting muscarinic antagonists (LAMA) are currently considered the therapeutic mainstay for patients with COPD and have been shown to improve clinical outcomes including symptoms, exercise capacity and airflow limitation. ... -
Using big data to assess prescribing patterns in Greece: The case of chronic obstructive pulmonary disease
(2016)Introduction: Chronic Obstructive Pulmonary Disease (COPD) is one of the top leading causes of death and disability, and its management is focused on reducing risk factors, relieving symptoms, and preventing exacerbations. ...